Fang L M, Osterrieder W
Pharmaceutical Research Department, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Eur J Pharmacol. 1991 Apr 17;196(2):205-7. doi: 10.1016/0014-2999(91)90430-x.
Ro 40-5967 is a structurally novel Ca2+ channel blocker which binds to the [3H]desmethoxyverapamil receptor in cardiac membranes with a potency similar to that of verapamil but which has considerably fewer negative inotropic effects. In the present study, the inward Ca2+ current was measured in isolated myocytes with the whole-cell patch-clamp technique. It was found that at a physiological membrane potential (-80 mV) Ro 40-5967 was also less potent than verapamil in inhibiting this current, and that negative inotropy and Ca2+ channel blockade were correlated.